Therefore, we propose that metabolic reprogramming through the p62–Keap1–Nrf2 pathway stimulates growth of HCC cells and increases their tolerance to anti-cancer drugs (Fig. 10g). Here, NFE2L2 is linked to hepatocellular carcinoma.